1. Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation
   Rao Fu et al, 2019, Acta Pharmacologica Sinica CrossRef
2. Effect of the Interrelation between CYP3A5 Genotype, Concentration/Dose Ratio and Intrapatient Variability of Tacrolimus on Kidney Graft Function: Monte Carlo Simulation Approach
   Nikola Stefanović et al, 2021, Pharmaceutics CrossRef
3. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience
   Nikola Z. Stefanović et al, 2020, European Journal of Drug Metabolism and Pharmacokinetics CrossRef
4. Influence of different formulations of tacrolimus on dosage regimen and drug exposure within the first year after kidney transplantation
   Nikola Stefanović et al, 2019, Hospital Pharmacology - International Multidisciplinary Journal CrossRef
5. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial
   Rita R. Alloway et al, 2017, PLOS Medicine CrossRef
6. Long-Term Kidney Transplant Outcomes: Role of Prolonged-Release Tacrolimus
   Bernhard Banas et al, 2020, Transplantation Proceedings CrossRef
7. Significance of Ethnic Factors in Immunosuppressive Therapy Management After Organ Transplantation
   Takaaki Yamada et al, 2020, Therapeutic Drug Monitoring CrossRef
8. Effect of ABCB1 3435C>T Genetic Polymorphism on Pharmacokinetic Variables of Tacrolimus in Adult Renal Transplant Recipients: A Systematic Review and Meta-analysis
   Wenxing Peng et al, 2020, Clinical Therapeutics CrossRef
9. Beyond Single Nucleotide Polymorphisms: CYP3A5∗3∗6∗7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients
   Daniel A. Brazeau et al, 2020, Frontiers in Genetics CrossRef
10. Pharmacogenomics and Precision Therapy in Prostate Cancer: Challenges and Perspectives
    Nikola Stefanović, 2024, Prostate Cancer CrossRef
11. Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients
    Mengyu Zhang et al, 2020, International Journal of Molecular Sciences CrossRef
12. Worsening of Kidney Transplant Function During 2-Year Follow-up Is Associated With the Genetic Variants of CYP3A4, MDR1, and UGT1A9
    Ewa Hryniewiecka et al, 2020, Transplantation Proceedings CrossRef
13. Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes
    Shu-Fang Zhang et al, 2022, Xenobiotica CrossRef
14. CYP3A5 and ABCB1 Polymorphisms in Living Donors Do Not Impact Clinical Outcome After Kidney Transplantation
    Lin Yang et al, 2018, Pharmacogenomics CrossRef
15. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients
    Fabiana D.V. Genvigir et al, 2016, Pharmacogenetics and Genomics CrossRef
16. Lack of Relationship Between Renal Function and Genetic Variants of CYP3A4, CYP3A5, MDR1, MRP2, UGT1A9, UGT1A8, and UGT2B7 in Patients After Liver Transplantation in a 2-Year Follow-up
    Ewa Hryniewiecka et al, 2020, Transplantation Proceedings CrossRef